Crossmark

Reversible posterior leukoencephalopathy syndrome (RPLS) in a patient with chronic lymphocytic leukemia (CLL) treated with Acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor: a case report

Crossref DOI link: https://doi.org/10.1007/s13760-024-02686-8

Published Online: 2024-11-25

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Janssens, Lise

Huybrecht, Silke

De Blauwe, Sofie

Vanopdenbosch, Ludo

Parmentier, Heleen
License Information

Text and Data Mining valid from 2024-11-25

Version of Record valid from 2024-11-25
More Information

Article History

Received: 13 October 2024

Accepted: 10 November 2024

First Online: 25 November 2024

Change Date: 10 November 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s13760-025-02933-6

Declarations

:

: The authors declare no competing interests.

Updates are available Correction dated 2025-11-10

Click to view Correction: https://doi.org/10.1007/s13760-025-02933-6